



Scorecards:

Ranking the companies in ASN Beleggingsfondsen investment universe

Based on the report “from policy to practice”

March 2021

Introduction to Scorecards

In 2016, ASN Bank followed up on the findings in the Sustainalytics report ('from policy to practice'). Since then we engaged in talks with ten companies in the investment universe of ASN Beleggingsfondsen (ASN Investment Funds). In order to assess where the companies stood and the progress they made, we created scorecards to guide our dialogue with these companies. From the evaluation report of March 2019 stems that while the pharmaceutical sector has made progress in recent years, further progress is yet to be made. Four companies from the initial engagement were excluded from our investment universe after thorough evaluation and one company was already removed before due to serious controversies. For the five remaining companies in our investment universe, we provide for an update with these scorecards. We also have developed a first scorecard for Merck KGaA as it was included in the universe in the beginning of 2019.

Before dealing with the individual scorecards, we would like to elaborate on our line of thought. How did we arrive at this approach?

As an investor, we have identified serious misconduct in this industry for a number of years now. A closer look reveals that these controversies can roughly be divided into four topics: ethical conduct, development and distribution, marketing, and remuneration (volume-driven sales targets).


As most of the companies have proper policies in place for these topics, the primary cause of this misconduct – according to our analysis – is the lack of implementation of these policies and often also the lack of a vision that sufficiently addresses society's expectations (developing useful, reliable and good medicines).

As a result, consumers suffer the negative consequences of misconduct and society's mistrust of the industry is growing.

The industry can (hopefully) regain this trust by formulating a vision that focuses on society, by implementing policy, by being transparent and through accountability, allowing consumers and patients to have complete faith in its products once again.

The industry still has a long way to go. Using the scorecards below, however, we will call companies to account about their vision (or their lack of a vision) and how they implement their policies and commitments.

Please find below the description and the elements that we assess across the four different topics: ethical conduct, development and distribution, marketing, and remuneration.




What is ASN Bank's contribution?

- use scorecards to measure and trace the level of transparency and accountability of the selected companies
- raise questions at shareholders' meetings
- engage in dialogue with companies in ASN's Investment Universe
- inform other stakeholders (investors, CSOs, clients)

The rationale behind our ratings

When companies adopt policies, implement them, and are transparent about the positive and negative effects and the obstacles they encounter in practice, they become accountable for their conduct. Aside from an overarching vision, we believe this to be the basis for better alignment with society's expectations. We have structured our scorecards accordingly. Set out below is an explanation of what the various ratings mean, followed by the scorecards (one for each of the ten companies assessed).



**/Renders account*

Description of the ratings

- 1) **Not transparent and no procedures**
- 2) **Basic procedures**

The company has limited procedures in place and does the minimum to counter bribery and corruption and to promote ethical conduct.
- 3) **Internally implemented**

The company has internally implemented the basic procedures.
- 4) **Externally verified**

The company has internally implemented the basic procedures and subjects them to external verification.
- 5) **Transparent and accountable**

The company has internally implemented the basic procedures and discloses the findings of internal and external verifications. As a result, the company is transparent and can be held accountable for its responsibilities.

Ethical conduct

What procedures does the company have in place to counter conduct it has prohibited in its rules of conduct (such as bribery, corruption and fraud of and/or by staff and executives) and to promote ethical behaviour?

- **Not transparent and no procedures**
- **Basic procedures**

The company has a whistleblower programme in place under which misconduct can be reported anonymously 24/7. The company actively informs staff of the policy and the whistleblower programme. Violations of the rules are subject to sanctions.
- **Internally implemented**

The company not only meets the basic procedures, but also engages in internal audits. Executives and managers are responsible for policy compliance. In addition, staff undergo annual training to ensure that they are familiar with the contents of the rules of conduct.
- **Externally verified**

The company not only meets the basic procedures and internal implementation, but also engages in external audits in addition to the audits that are legally required.
- **Transparent and accountable**

The company meets the basic procedures and internal implementation and engages in external audits. In addition, the company is transparent. It takes responsibility for its operations by declaring its rules of conduct applicable to third parties as well. It discloses the audits and the progress made in this regard. For example, the company publishes how many instances of misconduct have been reported and what action it has taken to resolve misconduct.

Development and distribution

What procedures does the company have in place to develop, manufacture and distribute safe and healthy medicines?

- **Not transparent and no procedures**
- **Basic procedures**

The company monitors the safety of its medicines. It has an action plan in place that takes effect when misconduct is detected. It has a system in place to take action in case of emergency.
- **Internally implemented**

The company not only meets the basic procedures, but also engages in internal audits.
- **Externally verified**

The company not only meets the basic procedures and engages in internal audits, but also engages in external audits in addition to the audits that are legally required.
- **Transparent and accountable**

The company not only meets the basic procedures and engages in internal and external audits but is also transparent and takes responsibility for its operations. It publishes on successful and terminated clinical trials through independent sources, while disclosing the raw data of the tests. The company also publicly reports on the findings of the audits.

Marketing

What procedures does the company have in place to ensure that medicines are placed on the market in a responsible manner?

- **Not transparent and no procedures**
- **Basic procedures**

The company has joined or endorses leading initiatives in this regard. This also entails that the company has translated these into internal policies. The company applies specific guidelines and gives its staff pointers on how to deal with healthcare professionals. The company continuously analyses the risks of the markets in which it operates.
- **Internally implemented**

The company not only meets the basic procedures, but also enforces internal compliance. The company ensures compliance by means of executive responsibility, inclusion of the basic procedures in internal audits and annual staff training, in order to make them aware of what is expected of them in this regard.
- **Externally verified**

The company not only meets the basic procedures and internal implementation, but also includes this topic in external audits.
- **Transparent and accountable**

The company not only meets the basic procedures, internal implementation and external verification, but is also transparent and takes responsibility for its operations. The company discloses misconduct as well as the action it has taken to resolve this misconduct. It also discloses what payments it makes to healthcare professionals. The company's aim is to terminate payments made to healthcare professionals for marketing purposes.

Remuneration

What procedures does the company have in place to encourage ethical conduct by employees through their remuneration?

- **Not transparent and no procedures**
- **Basic procedures**

The company aspires to terminate the sales volume-based remuneration of sales staff.
- **Internally implemented**

The company meets the basic procedures and implements them internally by setting goals and deadlines.
- **Externally verified**

The company not only meets the basic procedures and has implemented them internally, but also publicly reports on the progress made with the implementation of policy.
- **Transparent and accountable**

The company not only meets the basic procedures, internal implementation and external verification, but is also transparent and takes responsibility for its operations. It does so by rewarding sales staff on the basis of the quality of their services instead of the number of products they have sold.

NB: Two additional remarks regarding the ratings:

- * In some cases, a company's rating is a combination of two weightings, for example: "internally implemented/externally verified". This means that the company does not fully comply with the elements of either rating but does comply with one or more elements of both ratings.
- ** In some cases, companies do not have all elements of a rating. In those cases, we give the company the benefit of the doubt and award them that rating nonetheless.

Scorecards per company

- Astellas Pharma	P. 7
- AstraZeneca	P. 8
- GlaxoSmithKline	P. 9
- Merck KGaA	P. 10
- Novo Nordisk	P. 11
- Orion Oyj	P. 12

Astellas Pharma

Astellas Pharma Inc. manufactures, markets, imports and exports pharmaceutical products worldwide. The company focuses on oncology, urology, nephrology, immunology and neurology. Products made by the company include Prograft, Vesicare, Betanis and Harnal. The company was founded in 1923 and is headquartered in Tokyo, Japan.

Ethical conduct

Internally implemented

The company does not meet one of the criteria for *internally implemented*, specifically that board responsibility for ethical conduct is missing. However, we have decided to give the company the benefit of the doubt as it does meet all of the other conditions for *internally implemented*. Its rating is insufficient for *external verification* and *transparency*. Missing criteria include:

- external audits;
- disclosure of the number of whistleblower reports received, the types of misconduct and the measures taken.

Development and distribution

Transparent and accountable

The company received this rating because it meets all of the conditions for development and distribution.

Marketing

Externally verified

The company does not meet one of the criteria for *internally implemented*, specifically managerial responsibility for responsible drug marketing is missing. However, we have decided to give the company the benefit of the doubt as it does meet all of the other conditions for *externally verified*. Its rating is insufficient for *transparency*. Missing criteria include:

- disclosure of all payments made to healthcare professionals;
- public reporting on monitoring outcomes, violations and corrective action.

Remuneration

Not transparent and no procedures

The company received this rating because it does not meet any of the criteria it was screened for.

AstraZeneca

AstraZeneca PLC engages worldwide in the development, manufacture and marketing of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, autoimmune and infectious diseases, oncologic, neurological and vaccines. Its main products are Onglyza, Iressa, Faslodex, Zoladex, Pulmicort and Seroquel XR. AstraZeneca PLC was founded in 1992 and is headquartered in London, United Kingdom.

Ethical conduct

Internally implemented

The company received this rating because it meets all of the conditions for *internal implementation*. Its rating is insufficient for *external verification* and *transparency*. Missing criteria include:

- annual ethical conduct training for the board;
- external audits.

Development and distribution

Transparent and accountable

The company received this rating because it meets all of the conditions for development and distribution.

Marketing

Transparent and accountable

The company received this rating because it meets all of the conditions for marketing, except that it conducts regular risk assessments of the markets in which it operates. In May 2018 committed to publicly disclose all payments to health care professionals in all countries where it has commercial activities, even where it is not legally required. Although it not yet discloses all payments yet, it does show progress in this regard.

Remuneration

Not transparent and no procedures

The company received this rating because it does not meet any of the criteria it was screened for.

GlaxoSmithKline

GlaxoSmithKline plc develops and manufactures pharmaceutical products such as vaccines, over-the-counter medicines and consumer healthcare products, and markets them worldwide. Examples include medicines for the treatment of respiratory diseases, antivirals, medicines for the central nervous system and cardiovascular diseases, dermatology products, vaccines and HIV products. The company's well-known product brands include Panadol, Sensodyne and Aquafresh. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, United Kingdom.

Ethical conduct

Transparent and accountable

The company received this rating because it meets all of the conditions for ethical conduct.

Development and distribution

Transparent and accountable

The company does not meet one of the criteria for *basic procedures*, specifically that it has a system in place to take action in case of emergency. However, we have decided to give the company the benefit of the doubt because it does meet all of the conditions for *internal implementation*, *external verification* and *transparency*.

Marketing

Internally implemented

The company does not meet one of the criteria for *basic procedures*, specifically that it continuously analyses the risks of the markets in which it operates. However, we have decided to give the company the benefit of the doubt because it does meet all of the conditions for *internal implementation*. Its rating is insufficient for *external verification* and *transparency*. Missing criteria include:

- monitoring of compliance with rules, including external audits;
- public reporting on monitoring outcomes, violations and corrective action;
- disclosure of all payments made to healthcare professionals.

Remuneration

Basic procedures

The company meets two of all assessed criteria on this element. Its rating is insufficient for *internal implementation*, *external verification* and *transparency*. Missing criteria include:

- A formal policy promoting non-volume based sales target;
- A sales personnel remuneration strategy which eliminates volume-based targets;
- Quantitative targets or deadlines.

Merck

Merck KGaA manufactures, markets, imports and exports pharmaceutical products worldwide. The company focuses on oncology, endocrinology, multiple sclerosis, and fertility. Products made by the company include Rebif, Erbitux, Bavencio and Mavenclad. Besides the healthcare segment, the company also operates in the segments life sciences and performance materials. The company was founded in 1668 and is headquartered in Darmstadt, Germany.

Ethical conduct

Internally implemented

The company does not meet one of the criteria for *internally implementation*, specifically that board responsibility for ethical conduct is missing. However, we have decided to give the company the benefit of the doubt as it does meet all of the other conditions for *internally implementation*. Its rating is insufficient for *external verification* and *transparency*. Missing criteria include:

- external audits.

Development and distribution

Internally implemented

The company does not meet one of the criteria for *basic procedures*, specifically that it has procedures for incident investigation and corrective action. However, we have decided to give the company the benefit of the doubt as it does meet all of the other conditions for *basic procedures* and *internal implementation*. Its rating is insufficient for *external verification* and *transparency*. Missing criteria include:

- regular external safety audits in respect of products and services.

Marketing

Internally implemented

The company does not meet one of the criteria for *basic procedures*, specifically regular risk assessments of the markets it's operating in is missing. The company received this rating because it meets all of the conditions for *basic procedures* and *internal implementation*. Its rating is insufficient for *external verification* and *transparency*. Missing criteria include:

- disclosure of all payments made to healthcare professionals;
- monitoring of compliance with rules, including external audits.

Remuneration

Not transparent and no procedures

The company received this rating because it does not meet any of the criteria it was screened for.

Novo Nordisk

The company Novo Nordisk A/S engages in the development, manufacture and marketing of pharmaceutical products worldwide. In addition to products for the treatment of diabetes and haemophilia, it also offers products for growth hormone therapy and hormone replacement therapy. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsværd, Denmark.

Ethical conduct

Internally implemented

The company received this rating because it meets all of the conditions for *internal implementation*. Its rating is insufficient for *external verification* and *transparency*. Missing criteria include:

- external audits;
- disclosure of the number of whistleblower reports received, the types of misconduct and the measures taken.

Development and distribution

Externally verified

The company does not meet two of the criteria for *basic procedures*, specifically that it has procedures for incident investigation and corrective action and that there are regularly tested emergency response procedures. However, we have decided to give the company the benefit of the doubt as it does meet all of the other conditions for *internally implemented* and *externally verified*. Its rating is insufficient for *transparency*.

Marketing

Externally verified

The company does not meet one of the criteria for *basic procedures*, specifically regular risk assessments of the markets in which it operates is missing. However, we have decided to give the company the benefit of the doubt as it does meet all of the other conditions for *internal implementation* and *externally verified*. Its rating is insufficient for *transparency*. Missing criteria include:

- disclosure of all payments made to healthcare professionals;
- public reporting on monitoring outcomes, violations and corrective action.

Remuneration

Not transparent and no procedures

The company received this rating because it does not meet any of the criteria it was screened for.

Orion Oyj

Orion Oyj develops, manufactures and sells medicines for people and animals worldwide. The company supplies medicines in the areas of the central nervous system, oncology and pneumology. It also produces generic medicines, over-the-counter medicines, ingredients for generic and patented medicines and vitamins. Further, the company supplies patented and generic veterinary medicines and distributes veterinary medicines produced by other international companies. The company was founded in 1917 and is headquartered in Espoo, Finland.

Ethical conduct

Internally implemented

The company does not meet one of the criteria for *basic procedures*, specifically that the whistleblower mechanism is operated by an independent party. However, we have decided to give the company the benefit of the doubt because it does meet all of the other conditions for *internally implemented*. Its rating is insufficient for *external verification* and *transparency*. Missing criteria include:

- board responsibility for ethical conduct;
- regular external audits;
- disclosure of the number of whistleblower reports received, the types of misconduct and the measures taken.

Development and distribution

Externally verified

The company received this rating because it meets all of the conditions for *external verification*. Its rating is insufficient for *transparency*. Missing criteria include:

- publication of all clinical trial results including the results of terminated trials;
- publication of all clinical trial results in credible databases or peer reviewed journals.

Marketing

Basic procedures

Internally implemented

The company received this rating because it meets the conditions for *basic procedures* but only partly meets the conditions for *internal implementation*. Its rating is insufficient for *external verification* and *transparency*. Missing criteria include:

- monitoring of compliance with rules, including worldwide internal and external audits;
- public reporting on monitoring outcomes, violations and corrective action.

Remuneration

Not transparent and no procedures

The company received this rating because it does not meet any of the criteria it was screened for.